We are live on ! Find out more
CC

Commodore Capital Portfolio holdings

AUM $1.73B
1-Year Est. Return 298.96%
This Fund
S&P 500
This Quarter Est. Return
+52.05%
1 Year Est. Return
+298.96%
3 Year Est. Return
+2,048.53%
5 Year Est. Return
+6,668.48%
10 Year Est. Return
–
AUM
$1.5B
AUM Growth
+$351M
Cap. Flow
-$18.6M
Cap. Flow %
-1.24%
Top 10 Hldgs %
60.18%
Holding
43
New
11
Increased
11
Reduced
12
Closed
4

Top Buys

Rank Stock Value
1
DFTX
Definium Therapeutics
DFTX
+$33.3M
2
KYTX icon
Kyverna Therapeutics
KYTX
+$25.5M
3
PHVS icon
Pharvaris
PHVS
+$24.6M
4
ORIC icon
Oric Pharmaceuticals
ORIC
+$23.8M
5
CATX icon
Perspective Therapeutics
CATX
+$18M

Top Sells

Rank Stock Value
1
VERA icon
Vera Therapeutics
VERA
+$81.4M
2
SLNO
Soleno Therapeutics
SLNO
+$24M
3
RYZB
RayzeBio, Inc. Common Stock
RYZB
+$23.9M
4
RYTM icon
Rhythm Pharmaceuticals
RYTM
+$21.9M
5
CABA icon
Cabaletta Bio
CABA
+$17.2M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MRUS
1
DELISTED
Merus
MRUS
$196M 13.13%
4,360,000
-387,373
-8% -$15.7M
VERA icon
2
Vera Therapeutics
VERA
$2.54B
$136M 9.13%
3,165,000
-2,285,000
-42% -$81.4M
NUVL
3
DELISTED
Nuvalent
NUVL
$112M 7.47%
1,487,756
+156,719
+12% +$12.5M
XENE icon
4
Xenon Pharmaceuticals
XENE
$6.32B
$93.3M 6.24%
2,167,793
– –
SYRE icon
5
Spyre Therapeutics
SYRE
$8.87B
$71.5M 4.78%
1,884,084
– –
ELVN icon
6
Enliven Therapeutics
ELVN
$3.78B
$69.9M 4.67%
3,973,245
+1,071,429
+37% +$16.4M
PCVX icon
7
Vaxcyte
PCVX
$7.89B
$58.7M 3.93%
860,000
-240,000
-22% -$16.6M
DFTX
8
Definium Therapeutics
DFTX
$5.73B
$54.8M 3.67%
+5,833,333
New +$33.3M
ALPN
9
DELISTED
Alpine Immune Sciences Inc
ALPN
$54.5M 3.64%
1,375,000
-235,000
-15% -$6.93M
ARVN icon
10
Arvinas
ARVN
$518M
$52.6M 3.52%
1,275,000
+275,000
+28% +$12M
RYTM icon
11
Rhythm Pharmaceuticals
RYTM
$7B
$45.5M 3.04%
1,050,000
-500,000
-32% -$21.9M
COGT icon
12
Cogent Biosciences
COGT
$6.79B
$43.2M 2.89%
6,425,000
+858,974
+15% +$5.31M
PHVS icon
13
Pharvaris
PHVS
$2.39B
$39.9M 2.67%
1,725,000
+925,000
+116% +$24.6M
CLDX icon
14
Celldex Therapeutics
CLDX
$2.77B
$36.4M 2.43%
866,468
+164,501
+23% +$6.75M
NKTX icon
15
Nkarta
NKTX
$162M
$34.2M 2.29%
3,165,000
+435,000
+16% +$4.52M
VRDN icon
16
Viridian Therapeutics
VRDN
$2.13B
$33.9M 2.27%
1,934,653
+10,579
+0.5% +$205K
CELC icon
17
Celcuity
CELC
$4.03B
$33.6M 2.25%
1,555,954
-198,750
-11% -$3.17M
KURA icon
18
Kura Oncology
KURA
$922M
$32.5M 2.18%
1,525,000
+276,938
+22% +$5.38M
CCCC icon
19
C4 Therapeutics
CCCC
$376M
$27.9M 1.86%
3,410,384
-389,616
-10% -$3.02M
ORIC icon
20
Oric Pharmaceuticals
ORIC
$1.25B
$27.5M 1.84%
+2,000,000
New +$23.8M
ABVX
21
Abivax
ABVX
$11B
$27.1M 1.81%
1,895,003
– –
CATX icon
22
Perspective Therapeutics
CATX
$332M
$25.1M 1.68%
+2,105,263
New +$18M
IMVT icon
23
Immunovant
IMVT
$8.09B
$24.3M 1.62%
750,990
-249,010
-25% -$9.08M
KYTX icon
24
Kyverna Therapeutics
KYTX
$450M
$22.7M 1.52%
+912,189
New +$25.5M
ENGN icon
25
enGene Therapeutics
ENGN
$122M
$21.2M 1.42%
+1,250,000
New +$15.3M
1
2

Similar funds

RIA
Regal Investment Advisors Kentwood, Michigan $1.73B AUM 17.74% 1-Year Est. Return
PAIM
Punch & Associates Investment Management Edina, Minnesota $1.73B AUM 27.65% 1-Year Est. Return
MCWS
McKinley Carter Wealth Services Wheeling, West Virginia $1.73B AUM 17.28% 1-Year Est. Return
VCA
Verdence Capital Advisors Hunt Valley, Maryland $1.72B AUM 24.88% 1-Year Est. Return
ESBC
E.S. Barr & Co Lexington, Kentucky $1.72B AUM 12.69% 1-Year Est. Return
MSR
Main Street Research Lakeville, Connecticut $1.72B AUM 48.78% 1-Year Est. Return
WJA
Willis Johnson & Associates Houston, Texas $1.72B AUM 16.93% 1-Year Est. Return
OMC
Oasis Management Company Grand Cayman, Cayman Islands $1.72B AUM 32.1% 1-Year Est. Return

Commodore Capital's Q1 2024 Portfolio in Review

As of Q1 2024, Commodore Capital held 43 positions worth $1.5B, up 31% from $1.14B the previous quarter. Its ten largest holdings account for 60% of the portfolio.

Commodore Capital's Q1 2024 filing shows 11 new, 11 increased, 12 reduced and 4 closed positions. Its largest new stake was Definium Therapeutics: 5,833,333 shares worth $54.8M. The largest sale was Vera Therapeutics, an estimated $81.4M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Commodore Capital's largest Q1 2024 buy was Definium Therapeutics: 5,833,333 shares worth $54.8M.
  • Commodore Capital added most to Pharvaris in Q1 2024, an estimated $24.6M increase.
  • Commodore Capital's biggest Q1 2024 reduction was Vera Therapeutics, cutting an estimated $81.4M.
  • Commodore Capital fully exited RayzeBio, Inc. Common Stock in Q1 2024, selling an estimated $23.9M.
  • Commodore Capital's ten largest holdings make up 60% of its $1.5B portfolio in Q1 2024.
  • Commodore Capital opened 11 new positions and closed 4 in Q1 2024.
  • Commodore Capital's portfolio value rose 31% quarter-over-quarter to $1.5B.

Based on Commodore Capital's 13F filing for Q1 2024, filed 15 May 2024.